Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. - Wikidata - wikimedia - TriplyDB

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

http://www.wikidata.org/entity/Q27853367

about

Crizotinib resistance: implications for therapeutic strategies Targeted therapies and immunotherapy in non-small-cell lung cancer Tackling ALK in non-small cell lung cancer: the role of novel inhibitors CIViC database Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer.The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer.Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer.Alectinib for treatment of ALK-positive non-small-cell lung cancer.Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer How might treatment of ALK-positive non-small cell lung cancer change in the near future?Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC.New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.MicroRNA-targeted therapeutics for lung cancer treatment.Pharmacological management of relapsed/refractory NSCLC with chemical drugs.Sequencing brain metastases and opportunities for targeted therapies.Targeted Treatment of Brain Metastases.[China Experts Consensus on the Diagnosis and Treatment of Brain Metastases of Lung Cancer (2017 version)].A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.Preoperative serum carcinoembryonic antigen levels are associated with histologic subtype, EGFR mutations, and ALK fusion in patients with completely resected lung adenocarcinoma.Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases.Control of brain metastases with alectinib in anaplastic lymphoma kinase-rearranged lung cancer Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status.Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.Highlights from the Literature.Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.Current chemotherapeutic regimens for brain metastases treatment.An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.The role of brigatinib in crizotinib-resistant non-small cell lung cancer.Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience.

P2860

4ab613be3e6fd904438d2855c423099124b44af2

P248

Q26738381-9433C616-A0A9-4AF1-B709-249D34C882A7 Q26738986-40FF052A-5A6D-45D3-8431-578EB6C5AA49 Q26740329-17582401-285E-4E7E-9829-51B51B139D27 Q27612411-88BF8A1C-0676-483B-8D42-CB06A1874BBE Q28071903-42E34D55-BC83-44DC-8A8B-CA4FDE98D73C Q33623108-86DD16BF-F087-4F72-A4C8-ACE5E4346BAA Q33679543-9ACF3BBE-4FBE-4D21-A8FD-2AD1DA021CFF Q37737536-0CE7B441-FBC3-4BAC-A61E-3444F9538CF8 Q38631019-7871BECD-CB47-450E-9084-ECE73636F896 Q38688750-92A7ADBA-5E0A-4BAD-8F04-F97264ACB48D Q38748356-37823061-EAEF-4A04-AB6D-100A5933C754 Q38763108-CF49F0DF-BE13-46AE-A678-59F5AA5C93E8 Q38792120-884F0C9E-2435-4354-839A-068C108B69FC Q38805618-40CD0CA5-027B-43A7-9D9D-3BFA2AEA3C45 Q38828319-06F487EB-F793-48BB-9F56-4876689686FF Q38830389-9F4AB9FC-85F9-452E-B6CF-A6DD3A7C87E6 Q38846823-925CCC78-A236-4F72-B1AA-90979A7C475F Q39007500-2B2A3F48-40A3-41BE-9272-3C2E7B5D4D09 Q39014580-A24C7F89-B15E-43FC-8CC2-25F9A1D5CEB2 Q39095285-DF52D822-2156-4240-9BC6-DE0BB119462F Q39177404-4105091D-32A4-4B61-819F-4FD0F19564D4 Q39192200-05DD4366-02E1-41A3-9069-C8E362E7205F Q40372968-1FD2710E-E67A-4625-98C5-62CA6734D680 Q40996780-AD624B88-EE06-4D90-BA78-1D92B2E07B86 Q41018576-EBA846CD-A35D-4518-898A-1A492F334AB4 Q41428337-072E1828-8C5C-45CB-8697-9AF5D126763E Q42318174-B4878AB2-85EC-4688-82CB-5400387FECE7 Q42339666-F0662844-9A18-47D4-A596-884EAE15EC35 Q42367836-93A6CF31-B7BA-406B-AB10-683512CF13B1 Q47108604-891A8B11-FB2E-4D8B-BD88-195DDA3453FC Q47113459-ED39AC3B-39CF-4709-95E6-E37E7629037E Q47351169-23F3F00B-A29C-441A-B2A6-8D5969225127 Q47777234-8630DA74-8AFE-4727-80D1-D52786372BE1 Q48109517-19822633-2F15-4AE3-8D43-E28522DABB53 Q48179589-D1BFF7CA-F7BA-41D8-9076-EFFA19205486 Q48512265-8AE1C922-5AF3-4A0F-B4D1-DD8A7E99793F Q50251062-E2E8D792-3315-4420-A584-63F83BB8FE8C Q52318443-64A4EA5C-4AB5-4D6B-94F7-64B2517565D7 Q52673089-20C965F1-8677-45F8-A4EC-048E44D47A31 Q54116816-BAA53428-796A-44FC-9646-B9A453B9465C

P2860

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

http://www.wikidata.org/entity/Q27853367

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@ast

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@en

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@nl

type

label

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@ast

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@en

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@nl

prefLabel

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@ast

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@en

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@nl

P1433

Q27853367-3B7381B3-07B8-442C-AEB5-5FA285E19F45

P1476

Q27853367-2E1ACA37-3493-40B0-8AC3-419114A3F831

P2093

Q27853367-08432450-4668-444A-B6E8-3C6D512F5DE7

Q27853367-2C5B6823-F674-451F-ADFD-4EAD064E45E0

Q27853367-3B35EE0E-6539-49D0-9090-5293FE8FDD17

Q27853367-45BDB9AA-85B7-4D7D-9BC4-E6791B02A6AD

Q27853367-757E2B1F-0A60-4A4E-8C00-270F015B8213

Q27853367-89408696-4D08-4D62-AA29-D2A8A30F0D96

Q27853367-89B3DC15-383B-4032-A902-0B1DDC2ED5E8

Q27853367-9E90BBE8-00F1-4F2F-812C-46DB163A33E7

Q27853367-A88DC7E7-8787-4FCF-A4FE-9BF6242B5611

Q27853367-B7577A7C-4FAC-4953-B7F6-9C7929B3BAD7

P304

Q27853367-DC581008-BC2C-49CA-A8A9-F78394269A6F

P31

Q27853367-EDCEB449-7A31-4DA3-A30B-50C8B22AAB5E

P3181

Q27853367-C044F4F4-A643-4E04-B88C-98866E00DDCD

P356

Q27853367-10BF881B-03AB-4782-9978-AF5A8361EEC2

P407

Q27853367-BCD23042-37E1-492A-B69D-350DBD515768

P433

Q27853367-AB4B003A-5A2C-45D3-B9CB-18740F21E594

P478

Q27853367-339C4195-4A77-4012-A7BD-F85DC339830D

P50

Q27853367-02ACC9CC-C580-44DB-955E-D5CCAC07FA83

Q27853367-20BF3023-463D-4DB2-A799-2508866CF8EF

Q27853367-BE0D05BE-7900-478B-B454-A0DA8C698A11

P577

Q27853367-BA5775F7-CB68-4B01-830B-1C88E749D69F

P5875

Q27853367-5E523820-E045-4868-9A4E-BB9A1B337496

P698

Q27853367-C175ECA8-DB68-41D4-B2CB-64A06F1B37C8

P921

Q27853367-8E9430B5-27DF-4837-A169-B3A7ED72A891

Q27853367-DE9E9612-F483-48F0-BC28-7B257079C286

P3181

P356

JCO.2015.63.5888

P1433

Journal of Clinical Oncology

P1476

Intracranial Efficacy of Crizo ...... er: Results From PROFILE 1014.

@en

P2093

Benjamin J Solomon

http://www.w3.org/2001/XMLSchema#string

Daniel B Costa

http://www.w3.org/2001/XMLSchema#string

Dong-Wan Kim

http://www.w3.org/2001/XMLSchema#string

Federico Cappuzzo

http://www.w3.org/2001/XMLSchema#string

Jennifer Tursi

http://www.w3.org/2001/XMLSchema#string

Jolanda Paolini

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Nakagawa

http://www.w3.org/2001/XMLSchema#string

Keith D Wilner

http://www.w3.org/2001/XMLSchema#string

Paulina Selaru

http://www.w3.org/2001/XMLSchema#string

Tarek Mekhail

http://www.w3.org/2001/XMLSchema#string

P304

2858-2865

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

559998

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2015.63.5888

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Fiona Blackhall

Enriqueta Felip

P577

2016-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

299471818

http://www.w3.org/2001/XMLSchema#string

P698

27022118

http://www.w3.org/2001/XMLSchema#string

P921